Cor­bus shares dip on mixed Phase 1 sol­id tu­mor da­ta for Nectin-4 ADC

Cor­bus Phar­ma­ceu­ti­cals re­port­ed en­cour­ag­ing ear­ly-stage re­sults for its Nectin-4 tar­get­ing ADC in var­i­ous types of can­cer, but a lack of re­sponse in cer­tain pa­tients caused …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER